GORTEC announces that the NIVOPOSTOP study (NCT03576417) met its primary endpoint of Disease-Free survival (DFS) across all comers high risk resected HNSCC. Combined with KN689 this represents the 2nd positive IO trial in the postop setting. prnewswire.com/news-releases/…

Am heutigen Holocaust-Gedenktag wie an jedem anderen Tag: #WeRemember. Die Stolpersteine vor unserem Eingang erinnern uns täglich daran, was sich nicht wiederholen darf.

Heute ist Welt-HPV-Tag ❗️ #DEGRO #RadOnc #Strahlentherapie #WeltHPVTag #Vaccination #getvaccinated

Hot of the press IJROBP - The Red Journal: Role of SABR in oligometastatic head and neck cancer: a GORTEC randomized trial Full text here: doi.org/10.1016/j.ijro…

1/ 🧨 OMET trial (GORTEC 2014-04) in oligometastatic HNSCC 👥 N=69, SABR alone vs SABR + chemo + cetuximab 🧪 Key finding: Similar 1-year OS without ⬇️QoL (SABR 55.2% vs chemo-SABR 53.3%). 🏆SABR alone had⬇️toxicity and QoL impact. 📉 Gr 3–4 tox: 8.8% (SABR alone) vs 60% 🧵

Great keynote lecture by Melvin LK CHUA | FRCR, PhD, FASCO on the treatment of #NPC, especially about the controversies regarding proton radiotherapy, cone-down concepts, and contouring recommendations after IC, at the EORTC Head-and-Neck Cancer Group Meeting in #Lyon. @EORTC_HNCG_YI Head and Neck Cancer International Group

🎉 I’m serving as Guest Editor, together with Dr. József Dudás, for the upcoming special edition of BMC Cancer: “Head and Neck Cancer: Resistance and Novel Therapeutic Targets” 🔗 biomedcentral.com/collections/hnc 🗓️ Submissions until Dec 1, 2025 Looking forward to your contributions!

Bladder Preservation Strategies MIBC - IBCG 2025 europeanurology.com/article/S0302-… Key ☢️ points: 💡 TMT = #1 bladder-sparing strategy ⚡ RT must include a radiosensitizer (e.g., 5FU+MMC, cisplatin) 📏 Standard RT dose: 55 Gy in 20 fx (BCON / BC2001) 🌀 ENI: NOT routinely recommended

Weiterer Meilenstein bei der personalisierten, maßgeschneiderten #Krebstherapie am #UKL: Mit Inbetriebnahme des hochmodernen ETHOS-Systems kann die #Krebsbehandlung in Echtzeit noch präziser, wirksamer und individuell abgestimmt erfolgen. Mehr dazu unter: uniklinikum-leipzig.de/presse/Seiten/…

Here it is! KEYNOTE-689 primary publication online now NEJM. It’s been an incredible journey with DAdkins Siteman Cancer Center @WUSM. All started in early 2010s / now with U.S. FDA approval and a new standard of care! Dana-Farber News Brigham and Women's Hospital Brigham and Women’s Department of Surgery

I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR. We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️

Why is World Radiotherapy Day happening on September 7th? It’s because 9/7/1953 is the day the first patient was ever treated with a modern linear accelerator at Hammersmith Hospital in London. #WorldRTDay #WRAD #OneVoiceForRadiotherapy Ref: jpneylon.github.io/ABR/PDFs/Artic…

This study and pathologic staging proposal are very well done. It fixes a major problem in the current AJCC 8 pathologic staging for p16 OPSCC, which is a profound imbalance in staging (towards stage I). The updated system essentially uses ENE to help further break down the

📢 Save the date! The 3rd HNCIG Meeting will be held in Faro, Portugal 🇵🇹 on 12–13 November 2025. 🌐 Virtual attendance available. 📩 Register your interest here: bit.ly/hncig2025 More details coming soon!

🌟 #HNCIG Young Investigator Committee Working Groups: 🔹 Oligometastatic Project 🔹 Survivorship 🔹 Artificial Intelligence (AI) 🔹 Secondary Analysis 🔹 PORTHES-OC More updates soon — stay tuned! Christina Henson, MD Alexander Rühle Pierluigi Bonomo Sujith Baliga Monali Swain Myrto K. Moutafi